Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Prospective Randomized Study of Incidence of Thromboembolic and Bleeding Events According to the Period of Warfarin Use Before and After Catheter Ablation of Paroxysmal Atrial Fibrillation in Low Risk Patients

We hypothesized that in patients with low CHADS-VASc score (2 or < 2), there is no difference in thromboembolic or bleeding events between patients with short term warfarin therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8 weeks after procedure).

Inclusion Criteria:

• Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter ablation
• Patients with CHADS-VASc score 2 or less than 2

Exclusion Criteria:

• Patients who do not consent to the study
• Permanent or persistent atrial fibrillation
• Patients who have underwent prior catheter ablation for atrial fibrillation
• CHADS-VASc score more than 2
• History of stroke
• LVEF <40%
• Significant liver or kidney dysfunction
• History of major bleeding during warfarin therapy